GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 508 [WO2023154282A1]
Compound class:
Synthetic organic
Comment: BBO-10203 is an oral PI3Kα:RAS interaction inhibitor. It docks covalently, close to the RAS binding domain of PI3Kα, blocking interactions with all RAS isoforms, but does not disrupt PI3Kα activity or insulin homeostasis [1]. This is a mechanism that has antitumour potential.
|
|
References |
1. Simanshu DK, Xu R, Stice JP, Czyzyk DJ, Feng S, Denson JP, Riegler E, Yang Y, Zhang C, Donovan S et al.. (2025)
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction. Science,: eadq2004 [Epub ahead of print]. [PMID:40504949] |
2. Xu R, Wang B, Wallace E, When P, Beltran PJ, Stice J, Sinkevicius K, Yang Y, Bisignano P, Lighthouse F et al.. (2023)
Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications. Patent number: WO2023154282A1. Assignee: Theras, Inc., Leidos Biomedical Research, Inc., Lawrence Livermore National Security, Llc. Priority date: 07/02/2023. Publication date: 17/08/2023. |